Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Denali Therapeutics Inc. (DNLI) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $25.53 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $25.53.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $25.77.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $26.39.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $26.37.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $25.53 10-Q · filed 2026-08-06 |
| 2026-03-31 | $25.77 10-Q · filed 2026-05-07 |
| 2025-12-31 | $26.39 10-K · filed 2026-02-26 |
| 2025-09-30 | $26.37 10-Q · filed 2025-11-06 |
| 2025-06-30 | $25.87 10-Q · filed 2025-08-11 |
| 2025-03-31 | $26.19 10-Q · filed 2025-05-06 |
| 2024-12-31 | $27.14 10-K · filed 2025-02-27 |
| 2024-09-30 | $26.98 10-Q · filed 2024-11-06 |
| 2024-06-30 | $27.85 10-Q · filed 2024-08-01 |
| 2024-03-31 | $27.02 10-Q · filed 2024-05-07 |
| 2023-12-31 | $28.72 10-K · filed 2024-02-28 |
| 2023-09-30 | $29.91 10-Q · filed 2023-11-07 |
| 2023-06-30 | $28.63 10-Q · filed 2023-08-08 |
| 2023-03-31 | $28.53 10-Q · filed 2023-05-08 |
| 2022-12-31 | $30.24 10-K · filed 2023-02-27 |
| 2022-09-30 | $30.25 10-Q · filed 2022-11-03 |
| 2022-06-30 | $30.22 10-Q · filed 2022-08-08 |
| 2022-03-31 | $30.43 10-Q · filed 2022-05-05 |
| 2021-12-31 | $27.76 10-K · filed 2022-02-28 |
| 2021-09-30 | $27.48 10-Q · filed 2021-11-04 |
| 2021-06-30 | $25.13 10-Q · filed 2021-08-04 |
| 2021-03-31 | $24.69 10-Q · filed 2021-05-05 |
| 2020-12-31 | $18.75 10-K · filed 2021-02-26 |
| 2020-09-30 | $18.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $17.85 10-Q · filed 2020-08-07 |
| 2020-03-31 | $17.53 10-Q · filed 2020-05-07 |
| 2019-12-31 | $15.13 10-K · filed 2020-02-27 |
| 2019-09-30 | $15.08 10-Q · filed 2019-11-06 |
| 2019-06-30 | $14.77 10-Q · filed 2019-08-06 |
| 2019-03-31 | $14.26 10-Q · filed 2019-05-08 |
| 2018-12-31 | $12.66 10-K · filed 2019-03-12 |
| 2018-09-30 | $12.31 10-Q · filed 2018-11-08 |
| 2018-06-30 | $11.84 10-Q · filed 2018-08-09 |
| 2018-03-31 | $11.17 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |